Royal DSM NV (DSM)-製薬・医療分野:企業M&A・提携分析

【英語タイトル】Royal DSM NV (DSM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA8010863)・商品コード:DATA8010863
・発行会社(調査会社):GlobalData
・発行日:2017年12月20日
・ページ数:62
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥55,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥83,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Royal DSM NV (DSM) is a life sciences and materials sciences company, which focuses on health, nutrition and materials sectors. The company offers a wide range of products such as anti-invectives, polyesters, vitamins and other ingredients, performance materials to diverse end markets. It provides products and services to animal and human health and nutrition, personal care, pharmaceuticals, dietary supplements, automotive, medical materials, food and beverages, packaging, electrical and electronics, coatings and paints, alternative energy, housing, life protection and bio-based materials markets. It has operations in Europe, Americas, Africa, the Middle East and Asia Pacific. DSM is headquartered at Heerlen, the Netherlands.

Royal DSM NV (DSM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Royal DSM NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Royal DSM NV, Medical Devices Deals, 2011 to YTD 2017 10
Royal DSM NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Royal DSM NV, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Verdezyne Raises US$48 Million In Venture Financing 13
Arecor Raises Funds Through Venture Financing 15
Partnerships 16
Aerie Pharma Enters into R&D Agreement with Royal DSM 16
OptiBiotix Health Enters into Co-Development Agreement with Royal DSM 17
Royal DSM Forms Joint Venture With JLL Partners 18
DSM Enters Into Co-Development Agreement With AdeTherapeutics 20
Royal DSM Forms Joint Venture With Sinochem Group 21
Provexis Enters Into Co-Development Agreement With DSM Nutritional Products 23
Equity Offering 24
Amyris Raises USD50 Million in Second and Final Tranche of Private Placement of Shares 24
Amyris Raises USD47 Million in First Tranche of Private Placement of Shares 25
ChromaDex Completes Private Placement Of Shares For US$3 Million 27
Debt Offering 28
Royal DSM Completes Public Offering Of Bonds Due 2024 For US$684 Million 28
Royal DSM Announces Public Offering Of Notes Due 2019 For US$412.84 Million 29
Royal DSM Completes Private Placement Of Bonds Due 2019 For US$405 Million 30
Acquisition 31
i-Health to Acquire UP4 Probiotics from UAS Labs 31
Royal DSM To Acquire Aland Nutraceutical 32
DSM Completes Acquisition Of Fortitech, Nutraceutical Company, For US$634 Million 33
Royal DSM Completes Acquisition Of Ocean Nutrition Canada For US$532.7 Million 35
DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 37
Viocare Acquires DSM Personalized Nutrition From Royal DSM 39
Royal DSM Acquires Martek Biosciences 40
Royal DSM NV – Key Competitors 42
Royal DSM NV – Key Employees 43
Royal DSM NV – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 47
Recent Developments 49
Strategy And Business Planning 49
Apr 03, 2017: Royal DSM Opens New Biotechnology Center in Delft, the Netherlands 49
Financial Announcements 50
Nov 02, 2017: DSM Reports Results First Nine Months 2017 50
May 02, 2017: DSM Q1 2017 Results 51
Feb 15, 2017: DSM reports 2016 results 52
Feb 14, 2017: DSM new presentation of accounts as from Q4 2016 56
Aug 02, 2016: DSM Q2 2016 results 57
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Royal DSM NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Royal DSM NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Royal DSM NV, Deals By Therapy Area, 2011 to YTD 2017 9
Royal DSM NV, Medical Devices Deals, 2011 to YTD 2017 10
Royal DSM NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Verdezyne Raises US$48 Million In Venture Financing 13
Arecor Raises Funds Through Venture Financing 15
Aerie Pharma Enters into R&D Agreement with Royal DSM 16
OptiBiotix Health Enters into Co-Development Agreement with Royal DSM 17
Royal DSM Forms Joint Venture With JLL Partners 18
DSM Enters Into Co-Development Agreement With AdeTherapeutics 20
Royal DSM Forms Joint Venture With Sinochem Group 21
Provexis Enters Into Co-Development Agreement With DSM Nutritional Products 23
Amyris Raises USD50 Million in Second and Final Tranche of Private Placement of Shares 24
Amyris Raises USD47 Million in First Tranche of Private Placement of Shares 25
ChromaDex Completes Private Placement Of Shares For US$3 Million 27
Royal DSM Completes Public Offering Of Bonds Due 2024 For US$684 Million 28
Royal DSM Announces Public Offering Of Notes Due 2019 For US$412.84 Million 29
Royal DSM Completes Private Placement Of Bonds Due 2019 For US$405 Million 30
i-Health to Acquire UP4 Probiotics from UAS Labs 31
Royal DSM To Acquire Aland Nutraceutical 32
DSM Completes Acquisition Of Fortitech, Nutraceutical Company, For US$634 Million 33
Royal DSM Completes Acquisition Of Ocean Nutrition Canada For US$532.7 Million 35
DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 37
Viocare Acquires DSM Personalized Nutrition From Royal DSM 39
Royal DSM Acquires Martek Biosciences 40
Royal DSM NV, Key Competitors 42
Royal DSM NV, Key Employees 43
Royal DSM NV, Other Locations 44
Royal DSM NV, Subsidiaries 44
Royal DSM NV, Joint Venture 47

★調査レポート[Royal DSM NV (DSM)-製薬・医療分野:企業M&A・提携分析] (コード:DATA8010863)販売に関する免責事項を必ずご確認ください。
★調査レポート[Royal DSM NV (DSM)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆